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Context. Opioid switching has been found to improve opioid responsiveness in
different conditions. However, data on opioid switching performed at home are
almost nonexistent, despite the fact that most patients are followed at home.
Objectives. The aim of this retrospective survey was to determine frequency,
indications, usefulness, and safety of opioid switching when treating advanced
cancer-related pain in patients followed at home.
Methods. A retrospective review of data from patients with advanced cancer
followed at home by three home care teams for a period of two years was
performed. Patients who had their opioids switched were selected. Reasons for
switching opioid doses and routes of administration and outcomes were collected.
Results. Two hundred one (17%) of 1141 patients receiving ‘‘strong’’ opioids
were switched. The mean Karnofsky Performance Status score was 35.6, and the
median survival was 30 days. The most frequent reason to switch was for
convenience, and the most frequent switch was to parenteral morphine. In most
patients, a better analgesic response was observed. Patients who were switched to
parenteral morphine had a shorter survival in comparison with other opioid
sequences (P< 0.0005). After switching, opioid doses were increased by 23% and
41%, after a week and at time of death, respectively.
Conclusion. Opioid switching was useful for most patients in the home
environment, at least in less complex circumstances, when done by experienced
home care teams. Prospective studies are needed to provide information about
the decision to admit to hospital for this purpose and the predictive factors that
may relatively contraindicate transportation to a facility in severely ill
patients. J Pain Symptom Manage 2013;45:298e304.  2013 U.S. Cancer Pain
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Management of cancer pain is one of the
most important goals of palliative care. Opi-
oids are the mainstay of moderate-to-severe
cancer pain management, and most patients
favorably respond to opioid therapy.1
Patients with advanced cancer spend most of
their time at home. The home setting has been
reported to be preferred by most patients and
relatives and seems to be the favored place of
death.2 In a large sample of patients, amanaged
home care system has been found to enable pa-
tients to receive adequate pain treatment in the
comfort of their own homes. Pain control was
unsuccessful in a minority of patients.3
However, relieving pain may be problematic
in some cases, particularly in the home care
setting, where some facilities are unavailable
and assistance is less intensive than in a hospice
or in palliative care units. Despite a preference
for care at home, patients are mainly trans-
ferred to hospital because of an acute medical
event, an uncontrolled symptom, such as pain,
imminent death, or the inability to provide
needed care safely at home.4
Patients with cancer often require escalating
doses of opioids to control their pain or over-
come the development of tolerance to opi-
oids.5 This can result in untoward effects.
Opioid switching has been found to improve
opioid responsiveness in different conditions.
Experience has shown that a failure to respond
to one opioid does not mean failure to re-
spond to all opioids, and opioid switching
may allow better pain control and also de-
crease adverse effects.6e11 Moreover, in some
circumstances, a change in the route of deliv-
ery and/or drug is dictated by other factors
in the home care setting, including conve-
nience, patient preference, or concomitant
problems, such as inability to swallow, cogni-
tive failure, and intestinal transit failure.12
Unfortunately, data on opioid switching per-
formed at home are almost nonexistent. The
Home CaredItaly group recently has been es-
tablished, with the intent to disseminate and
implement information on cancer patients fol-
lowed at home, given the paucity of existingdata in this setting. The objective of this retro-
spective study was to determine frequency, in-
dications, usefulness, and safety of opioid
switching in treating cancer-related pain in pa-
tients followed at home.Methods
We reviewed the charts of patients who were
followed by three home palliative care teams in
Turin, Genoa, and L’Aquila, for a period of
two years (2008e2009). These teams belong
to a home care network and share similar pro-
tocols and intervention modalities.
Patients were included in the study if they
were receiving ‘‘strong’’ opioids for chronic
cancer pain and were switched to another opi-
oid. Patients were excluded if they were receiv-
ing opioids for reasons other than pain. The
reasons for switching were collected: uncon-
trolled pain, adverse effects, or both, or conve-
nience (i.e., switched for other reasons in an
acceptable clinical situation, e.g., problems
with swallowing or patient request). Demo-
graphic data and Karnofsky Performance Sta-
tus score at the time of switching were
recorded, as well as opioid doses and their ini-
tial conversion ratio. Doses and ratios after one
week also were recorded.
The following parameters were collected for
the first switch (Switch 1): 1) previous opioid,
route, and dose; 2) initial doses of the second
opioid and route; 3) the dose and route of the
second opioid one week after performing the
switch; 4) the outcome, classified as: a) good
response, considered as good pain control
(<4/10 on a numerical scale) if patients
were switched for poor analgesia and/or ac-
ceptable improvement of adverse effects if pa-
tients had been switched for this reason;
b) partial response (all the intermediate situa-
tions between a and c); and c) poor response,
uncontrolled pain or adverse effects, need to
further switch or other alternatives; 5) opioid,
route of administration, and dose at time of
death; and 6) survival. The same data were col-
lected for further opioid switches (e.g.,
Switches 2, 3, and so on).
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Data were collected and analyzed using SPSS
Software v. 14.0 (SPSS, Inc., Chicago, IL). Sta-
tistical analysis of quantitative and qualitative
data, including descriptive statistics, was per-
formed for all the items. Frequency analysis
was performed with the Chi-squared test. The
paired samples Student’s t-test was used to
compare initial with final opioid conversion ra-
tios. The one-way analysis of variance was used
for parametric analysis. All P-values were two-
sided, and P-values of less than 0.05 were con-
sidered to indicate statistical significance.Results
A total of 1682 consecutive patients followed
at home during a two-year period were sur-
veyed; 1141 patients (67.8%) were receiving
‘‘strong’’ opioids for chronic cancer pain. No
patient was receiving opioids for reasons other
than pain (e.g., dyspnea). Two hundred one
patients were switched to other opioids
(17.6%) during home care.
One, two, or three opioid substitutions were
made for 201, 15, and two patients, respec-
tively. Descriptive data are presented in
Table 1. No statistical differences were found
in patients who were switched. The most fre-
quent reason to switch was for convenience,
with a large number of patients switched
from oral opioids, such as oral morphine
(OR MOR) and oral oxycodone (OR OXY),
to parenteral morphine (PR MOR) (52 pa-
tients) because they were no longer able to
take oral medications, particularly in the last
days of life. Uncontrolled pain was the second
most frequent reason to switch (66 patients forTable 1
Characteristics of Patients Who Were Receiv
Number of Patients Patien
Total 1682
Age 68
Gender (male) 902
Karnofsky score (mean) 40.5
Primary tumor
Lung 404
Gastrointestinal 313
Urogenital 252
Breast 143
Pancreas 134
Liver 60
Other 376uncontrolled pain and 27 patients for uncon-
trolled pain and other reasons). Sixteen and
22 patients were switched for adverse effects
only and for adverse effects and other reasons,
respectively. In most patients, the outcome was
good or partial, with a minority of patients who
were considered poorly responsive to opioid
switching (Tables 2e7).
The sequences of the first switch are shown in
Tables 2e7. Patients switched to PR MOR had
a shorter survival (median 15 days) in compari-
son with other sequences (oral hydromor-
phone, OR MOR, and OR OXY) (P< 0.0005).
After switching, opioid doses were modified
during the course of treatment, with
mean SD dose increments of 23.3 38.1%
and 41.4 70.1%, after one week and at the
time of death, respectively.
A minority of patients were switched again
(n¼ 15), and two patients were switched a third
time. The most frequent reason for a further
switch was inability to swallow (n¼ 10), and
PR MOR was the preferred choice (n¼ 8).Discussion
This retrospective study showed that opioid
switching performed in patients followed at
home is feasible and often yields favorable out-
comes. Although it was not possible to assess
the adequacy of the treatment in some cases,
given the retrospective nature of this study,
only four patients who could be assessed did
not respond positively to the change of opioid
or route of administration.
The frequency of opioid switching was 17.6%.
As expected, the switching rate was lower than
that observed in acute palliative care units,ing Opioids and Who Were Switched
ts Receiving Opioids Patients Who Were Switched
1141 201
70 69
601 116
38.5 35.6
306 53
208 43
132 32
71 17
65 17
37 8
322 31
Table 2
Patients Switched From TD FEN to Oral Opioids
n¼ 39
Dose of
Previous
Opioid (mg)
(Mean [SD])
Initial Dose
of Second
Opioid (mg) Initial Ratio
Dose at One
Week of
Second
Opioid (mg)
Final Ratio
After One
Week
Dose at
Death (mg) Outcome
7 TD FEN
2.0 (1.2)
OR OXY
87 (51)
0.027 (0.015) OR OXY
116 (78)
0.023 (0.016) 240 (0) A¼ 2
B¼ 4
C¼ 1
8 TD FEN
1.1 (0.6)
OR MOR
106 (77)
0.013 (0.008) OR MOR
106 (74)
0.012 (0.007) 151 (97) A¼ 8
23 TD FEN
2.18 (1.28)
PR MOR
84 (56)
0.029 (0.010) PR MOR
88 (61)
0.028 (0.010) 102 (75) A¼ 15
B¼ 2
NA¼ 6
1 TD FEN
1.8 (0.0)
OR HYD
28 (0)
0.06 (0) OR HYD
36 (0)
0.05 (0) 36 (0) B¼ 1
TD FEN¼ transdermal fentanyl; OR OXY¼oral oxycodone; A¼ good response; B¼ partial response; C¼ poor response; OR MOR¼ oral mor-
phine; PR MOR¼ parenteral morphine; OR HYD¼ oral hydromorphone; NA¼ not available.
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quently require opioid switching.1,12e16 In the
home setting, it is likely that the decision to
switch usually was dictated by the progressive
worsening of the clinical situation, preventing
oral administration of opioids, as suggested by
the shorter survival in this group of patients.
Although patients had variable courses,
many required an increase in the opioid dose
at time of death, in comparison with the doses
used for switching. The mean percentage in-
crement was about 40%. This observation
could be attributed to many factors, including
metabolic derangement, increasing pain, the
development of dyspnea, or psychological dis-
tress occurring at the end of life. This also is
confirmed by the high rate of switching be-
cause of the inability to swallow.
The limited number of patients for each opi-
oid sequence prevented further analysis re-
garding the relationship with the causes ofTable 3
Patients Switched From OR O
n¼ 72
Dose of
Previous Opioid
(mg) (Mean
[SD])
Initial Dose of
Second Opioid
(mg)
Initial Ratio
(Mean)
Dos
Week
Opi
11 Dose OR OXY
63.6 (29.7)
TD FEN
1.0 (0.5)
68.9 (37.6) 0
9 Dose OR OXY
32.2 (30.7)
OR MOR
59.7 (51)
0.53 (0.11) 50
52 Dose OR OXY
95.9 (114)
PR MOR
68 (64)
1.48 (1.11) 6
OR OXY¼oral oxycodone; TD FEN¼ transdermal fentanyl; A¼ good resp
response; PR MOR¼ parenteral morphine; C¼ poor response.
aP< 0.05.opioid switching. Most patients were switched
from the most common opioids used as first
choice, including transdermal fentanyl, OR
OXY, and OR MOR, reflecting the attitudes
of the opioid market in the country.
Although there was not a precise initial con-
version ratio ‘‘per protocol,’’ given the retro-
spective nature of the study, the ratios initially
used worked very well, although the doses often
needed changing after one week. This high-
lights the use of a prudent initial conversion ra-
tio, based on safety reasons in a setting like
home care. The final conversion ratios were in
line with previous studies performed in other
settings.12
Many patients were switched for conve-
nience rather than for improving analgesia
or to address adverse effects, with a large num-
ber of patients switched from oral opioids,
such as OR MOR and OR OXY, to PR MOR.
It is notable that many patients were switchedXY to Other Opioids
e at One
of Second
oid (mg)
Final Ratio
After One Week
Dose at Death
(mg) Outcome
.8 (0.3) 88.9 (69.4) 1.1 (0.6) A¼ 7
NA¼ 4
.8 (33.7) 0.69 (0.7) 52.1 (35.8) A¼ 7
B¼ 2
5 (42) 1.16 (0.52)a 78 (65) A¼ 27
C¼ 1
NA¼ 24
onse; NA¼ not available; OR MOR¼ oral morphine; B¼ partial
Table 4
Patients Switched From OR MOR to Other Opioids
n¼ 54
Dose of Previous
Opioid (mg)
(Mean [SD])
Initial Dose
of Second
Opioid (mg)
Initial
Ratio
Dose at One
Week of Second
Opioid (mg)
Final Ratio
After One
Week
Dose at
Death (mg) Outcome
17 OR MOR
57.1 (39.3)
TD FEN
0.8 (0.4)
72 (33.9) TD FEN
0.9 (0.5)
58.3 (32.7) 1.2 (0.6) A¼ 15
B¼ 1
NA¼ 1
4 OR MOR
51.2 (40.9)
OR OXY
56.2 (53)
1.13 (0.3) OR OXY
76.2 (75)
1.02 (0.5) 70 (71) A¼ 4
27 OR MOR
72.5 (70.9)
PR MOR
26.7 (21.6)
2.51 (0.9) PR MOR
33.2 (30.1)
2 (0.7)a 38 (34.4) A¼ 24
B¼ 2
EXITUS¼ 1
2 OR MOR
17.5 (3.5)
TD BUP
0.8 (0)
21.9 (4.4) TD BUP
0.8 (0)
21.9 (4.4) 0.8 (0) A¼ 2
4 OR MOR
33.7 (20.5)
OR HYD
9.0 (5)
3.75 (1.0) OR HYD
9.0 (5)
3.75 (1.0) 15 (5) A¼ 4
OR MOR¼ oral morphine; TD FEN¼ transdermal fentanyl; A¼ good response; B¼ partial response; NA¼ not available; OR OXY¼oral oxyco-
done; PR MOR¼ parenteral morphine; TD BUP¼ transdermal buprenorphine; OR HYD¼ oral hydromorphone.
aP< 0.05.
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attitudes about changing the route of adminis-
tration in the last days of life, when patients are
expected to be unable to swallow.
Data regarding opioid switching at home are
lacking for comparison with the present data.
In a multicenter prospective study, about
75% of patients assessed were outpatients or,
more often, home care patients. The true
opioid switching rate was about 12% and was
higher in the inpatient setting.17 Interestingly,
change to the parenteral route accounted for
a further 30% of opioid substitutions.
Of interest, methadone was practically ex-
cluded from opioid switching. Dosing of this
drug can be challenging for practicing physi-
cians.18 This is true as well in the home care
setting, where monitoring is obviously less
likely than in a hospital setting.Table 5
Patients Switched From TD B
n¼ 22
Dose Previous
Opioid (mg)
(Mean [SD])
Initial Dose of
Second Opioid
(mg) Initial Ratio
Do
Wee
Op
8 TD BUP
1.5 (0.2)
TD FEN
1.4 (0.5)
1.26 (0.41)
1
4 TD BUP
1.62 (0.33)
OR OXY
55 (19)
0.03 (0.01) O
6
5 TD BUP
0.88 (0.33)
OR MOR
58 (39)
0.019 (0.01) O
4 TD BUP
1.1 (0.6)
PR MOR
31.3 (23.2)
0.04 (0.03) P
47
1 TD BUP
0.8 (0.0)
OR HYD
16 (0)
0.05 (0) O
TD BUP¼ transdermal buprenorphine; TD FEN¼ transdermal fentanyl; A
OXY¼oral oxycodone; NA¼ not available; OR MOR¼ oral morphine; PR MThere are only two studies assessing opioid
switching at home, both of which involved
changes to methadone. In an early experience
in patients followed at home or as outpatients,
a rapid switching from OR MOR to small doses
of methadone was effective by using an initial
conversion ratio of 5:1.19 In another study, 14
home care patients were switched from about
120 mg/day of OR MOR equivalents to a stable
dose of 40 mg/day of methadone. Ten patients
improved after switching to methadone, but
one patient developed severe delayed toxicity,
and another one received an initial dose 10
times higher than that prescribed for four
days.20
There are other data pertinent to outpatient
switching to methadone. In a retrospective
analysis of 29 heavily pretreated patients, the
starting dose of methadone was about 25 mgUP to Other Opioids
se at One
k of Second
ioid (mg)
Final Ratio After
One Week
Dose at
Death (mg) Outcome
TD FEN
.7 (0.8)
1.06 (0.37) 2.0 (0.8) A¼ 6
B¼ 1
C¼ 1
R OXY
2.3 (33)
0.03 (0.01) 120 (0) A¼ 3
NA¼ 1
R MOR
70 (40)
0.017 (0.01) 62 (25) A¼ 5
R MOR
.5 (45.9)
0.020 (0.0) 37.5 (30.7) A¼ 2
NA¼ 2
R HYD
16 (0)
0.05 (0) 16 (0) A¼ 1
¼ good response; B¼ partial response; C¼ poor response; OR
OR¼ parenteral morphine; OR HYD¼ oral hydromorphone.
Table 6
Patients Switched From OR HYD to Other Opioids
n¼ 8
Dose of Previous
Opioid (mg)
(Mean [SD])
Initial Dose of
Second Opioid
(mg) Initial Ratio
Dose at One
Week of Second
Opioid (mg)
Final Ratio After
One Week
Dose at Death
(mg) Outcome
1 OR HYD
8.0 (0.0)
TD FEN
0.6 (0)
13.3 (0) TD FEN
0.6 (0)
13.3 (0) 0.9 (0) A¼ 1
2 OR HYD
15 (9.9)
OR OXY
40 (0)
0.37 (0.25) OR OXY
52 (16)
0.28 (0.10) d A¼ 1
B¼ 1
2 OR HYD
14 (14.1)
PR MOR
90 (42)
0.13 (0.09) PR MOR
90 (42)
0.13 (0.09) 190 (155) A¼ 2
3 OR HYD
16 (13.8)
PR MOR
43.3 (32.1)
0.36 (0.07) PR MOR
25.0 (7.1)
0.33 (0.09) 43.3 (32.1) A¼ 3
OR HYD¼ oral hydromorphone; TD FEN¼ transdermal fentanyl; A¼ good response; OR OXY¼oral oxycodone; B¼ partial response; PR
MOR¼ parenteral morphine.
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The duration of titration was 32 days.21 Retro-
spective data on 89 rotations to methadone
conducted in an outpatient setting of a com-
prehensive cancer center have been recently
reviewed. Patients receiving about 100 mg of
OR MOR equivalents were switched to oral
methadone. The methadone dose at the first
and the second follow-up visits was 15 mg/
day and 18 mg/day, respectively. The interval
between the first prescription and the two
follow-up visits was about 15 days. This
approach provided an overall success rate of
85%.22 It is likely that these ambulatory pa-
tients were in a different condition than the
patients reported in this survey; performance
status was likely to be higher than in a sample
that had a mean survival of about four weeks
and required a rapid solution to the problem.
There are some limitations to this study, in-
cluding the retrospective design and the rela-
tively low number of patients who were
switched. The home care teams participating
in this study were chosen according to the
quality of the service offered to patients andTable 7
Patients Switched From PR M
n¼ 6
Dose of Previous
Opioid (mg)
(Mean [SD])
Initial Dose of
Second Opioid
(mg) Initial Ratio
Do
Week
Op
3 PR MOR
50 (60)
TD FEN
0.7 (0.5)
55.6 (38.5) T
1
1 PR MOR
60 (0)
OR OXY
60 (0)
1 (0) O
1
2 PR MOR
10 (0)
OR MOR
25 (7)
0.42 (0.1) O
4
PR MOR¼ parenteral morphine; TD FEN¼ transdermal fentanyl; A¼ good
MOR¼ oral morphine.families, similar programs, and experience in
research and are not representative of the level
of home care in Italy. These data cannot
be generalized, as there is no global informa-
tion on the clinical activities of home care in
Italy.
Opioid switching may improve opioid re-
sponse. Although the present survey has limi-
tations, it suggests that opioid switching in the
home environment by experienced home
care teams is feasible for most patients, at
least in less complex circumstances. Prospec-
tive studies are needed to provide more infor-
mation about the approach, including the
factors that would support a decision to admit
to hospital and those that would relatively
contraindicate transportation in severely ill
patients.Disclosures and Acknowledgments
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of interest.OR to Other Drugs
se at One
of Second
ioid (mg)
Final Ratio After
One Week
Dose at
Death (mg) Outcome
D FEN
.1 (0.6)
36.1 (26.8) 1.4 (0.7) A¼ 2
B¼ 1
R OXY
20 (0)
0.5 (0) 160 (0) A¼ 1
R MOR
8 (16)
0.22 (0.07) 65 (7) B¼ 2
response; B¼ partial response; OR OXY¼oral oxycodone; OR
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